Current and Future Prospects for a Vaccine for Nontypeable Haemophilus influenzae

Abstract

Nontypeable Haemophilus influenzae is an important human respiratory tract pathogen that causes about 30% of otitis media in infants and children. This proportion is increasing as a result of pneumococcal conjugate vaccines. Because of the morbidity associated with otitis media, a strong rationale exists to develop strategies to prevent these infections. A challenge to developing a vaccine for nontypeable H. influenzae is the antigenic heterogeneity of several major surface antigens and the genetic heterogeneity among strains. Several research groups have identified conserved surface proteins and tested them as putative vaccines. A recent clinical trial with protein D, a conserved surface antigen, demonstrated partial efficacy in preventing H. influenzae otitis media. This important result provides a proof of principle for developing a vaccine to prevent otitis media caused by nontypeable H. influenzae. Several vaccine antigens for nontypeable H. influenzae are in development.